Adnan Kastrati, MD

Country Germany
Specialty Interventional Cardiologist
  1. Very Long-term Outcomes of DES
  2. Revascularization in Patients with STEMI and Multivessel Disease
  3. Which Contemporary DES Do You Prefer? and Why?
  4. Updated DES Trials: Contemporary and Future Devices
  5. Updated Evidence of LM Stenting Between PCI vs. CABG Since TCTAP 2011
  6. Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive
  7. ISAR-DESIRE3: DEB, Desirable Option for DES-ISR
  8. Periprocedural Antithrombotic Therapy During PCI - Lessons from ISAR-REACT 1, 2, 3, 4, Trials
  9. Tailoring Antiplatelet Therapy for the Different Types of ACS-PCI Patients
  10. [Bivalirudin: Is It Standard of Care in the Cath Lab?] Yes, It Should Be Indicated for All Patients with STEMI.
  11. Glycoprotein IIb/IIIa Inhibitors at Primary PCI in STEMI (BRAVE-3, ON-TIME2, HORIZONS-AMI, MULTISTRATEGY, and FINESSE)
  12. Clopidogrel vs. New Antiplatelet Therapy (Prasugrel)
  13. Systemic Review of Longterm Outcomes after First- vs. Second-Generation DES
  14. Does PCI Reduce Mortality? A Meta-Analysis of 17 Studies Comparing PCI (Bare Metal and Drug-Eluting Stents) vs. Medical Therapy
  15. ISAR-LEFT MAIN: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions
  16. Optimizing Antiplatelet Therapy in PCI/ Antiplatelet Therapy After PCI: How Much and How Long?
  17. Pushing the Envelope for Bivalirudin Monotherapy: Design, Rationale, and Status of ISARREACT-4 and HORIZONS
  18. ISAR-CHOICE-2: Randomized Trial of 75 mg vs 150 mg of Daily Clopidogrel in Patients Undergoing PCI
  19. Bivalirudin on Trial: Rationale and Status of ISAR-REACT 3 and 4
  20. Predictors of DES Restenosis: Results from a Large Database